Analysis of Adherence to Fluoxetine Treatment through its Plasma Concentration

Abstract Depression plays an important role in non-adherence to medical recommendations. Fluoxetine is a first line of depression treatment. This study aimed to evaluate adherence to drug therapy in fluoxetine users by different methods. A cross-section study was conducted with 53 depressed patients on fluoxetine for at least six months. Drug therapy adherence was assessed by validated questionnaires [Brief Medication Questionnaire (BMQ) and Morisky-Green test (MG)] and by the blood concentration of fluoxetine and its active metabolite norfluoxetine. Blood samples were taken before the daily first dose of fluoxetine. The plasmatic concentration of fluoxetine and norfluoxetine indicated that 58.5% volunteers were within the recommended therapeutic range and thus considered adherent to drug therapy. However, questionnaires indicated a non-adherent majority: 41.5% patients had a high degree of adherence in MG and only 13.2% were adherent to pharmacological treatment in BMQ. Most fluoxetine users showed a plasma concentration of fluoxetine and norfluoxetine within the therapeutic range, despite the low adherence to the drug therapy evaluated by the questionnaires. Thus, we suggest that plasma levels of fluoxetine and norfluoxetine could be used as the main method to check adherence to treatment.

Seasonal variation of vitamin D among healthy adult men in a subtropical region

SUMMARY OBJECTIVE: To evaluate seasonal variation of 25(OH)vitamin D [25(OH)D3] levels, and factors associated with it, in healthy adult men, who exercised outdoors for 50 min., at least twice a week, from 10AM to 4PM, in a Brazilian semitropical region. METHODS: Blood samples were collected at the end of each season for 25(OH)D3, measured by liquid chromatography with tandem mass spectrometry. Ultraviolet irradiation was estimated by radiometer, calculating the daily photobiological response to vitamin D synthesis in human skin (D-VitD). The prevalence of 25(OH)D3 <20ng/mL changed with the seasons (p=0.000): 8.7% (n=6/69), 1.5% (n=1/66), 0 (n=0/64), and 21.7% (n=13/60), respectively, at the end of winter, spring, summer, and autumn. The prevalence, adjusted for multiple comparisons, was higher in winter than summer (p=0.026), and in autumn than spring (p=0.001) and summer (p=0.000). There were no associations of 25(OH) D3 levels with BMI (p=0.207), body fat (p=0.064), and phototype (p=0.485), in univariate analysis. It was associated with D-VitD in the 30 days before blood sampling (p=0.000), after adjustment to body fat. The prevalence of 25(OH)D3 <30ng/mL varied seasonally (p=0.000): 69.6% (n=48/69), 68.2% (n=45/66), 43.8% (n=28/64), and 88.4% (n=53/60), respectively, in winter, spring, summer, and autumn. CONCLUSIONS: In a Brazilian subtropical region, a seasonal variation in 25(OH)D3 was observed in healthy adult males, although they spent at least 50 min outdoors twice a week, wearing shorts and T-shirts. 25(OH)D3 <20ng/mL was 21.7% in autumn; D-vitD 30 days prior to blood sampling was the only factor independently associated with 25(OH)D3 levels.

RESUMO OBJETIVOS: Avaliar a sazonalidade da 25(OH)vitamina D3 [25(OH)D3] e fatores associados em homens adultos saudáveis, que se exercitavam ao ar livre pelo menos 50 min duas vezes por semana, das 10 às 16h, em uma região subtropical. MÉTODOS: Sangue foi colhido no fim das estações para medir 25(OH)D3, por cromatografia líquida em tandem com espectroscopia de massas. A radiação ultravioleta foi estimada por radiômetro, calculando diariamente a resposta fotobiológica para sintetizar vitamina D na pele humana (D-VitD). RESULTADOS: A prevalência de 25(OH)D3 <20ng/mL foi sazonal (p=0.000): 8.7% (n=6/69), 1.5% (n=1/66), 0% (n= 0/64), e 21.7% (n=13/60), respectivamente, no final do inverno, primavera, verão e outono. A prevalência, ajustada para comparações múltiplas, foi maior no inverno do que no verão (p=0.026) e no outono do que na primavera (p=0.001) e verão (p=0.000). A 25(OH)D3 não se associou com o índice de massa corporal (p=0.207), gordura corporal (p=0.064) ou fototipo (p=0.485), na análise univariada. Associou-se à D-VitD nos 30 dias antes da coleta de sangue (p=0.000), ajustada para gordura corporal. Houve sazonalidade na prevalência de 25(OH)D3 <30ng/mL (p=0.000): 69.6% (n=48/69), 68.2% (n=45/66), 43.8% (n=28/64), e 88.4% (n=53/60), respectivamente, no inverno, primavera, verão e outono. CONCLUSÕES: Em uma região subtropical, houve sazonalidade na 25(OH)D3 em homens adultos, saudáveis, embora se exercitassem ao ar livre pelo menos 50 minutos duas vezes por semana, usando shorts e camiseta. 25(OH)D3 <20ng/mL foi 21.7% no outono e a D-vitD 30 dias antes da coleta do sangue foi o único fator associado de modo independente à 25(OH)D3.

Factors related to decreased vitamin D levels in men with spinal cord injury living in a subtropical region / Fatores relacionados a níveis reduzidos de vitamina D em homens com lesão da medula espinhal vivendo em uma região subtropical

AIMS: To evaluate the levels of vitamin D, parathyroid hormone and calcium in individuals with spinal cord injury and to identify related factors. METHODS: A cross-sectional study included men with spinal cord injury, living in the South Region of Brazil. A questionnaire was applied to evaluate socioeconomic data, life habits and health. The time elapsed since the spinal cord injury was considered. Vitamin D was evaluated in plasma via liquid chromatography; calcium and PTH were measured in serum by a colorimetric method and electrochemiluminescence respectively. For data analysis, linear regression and chi-square test were utilized. Values of p<0.05 were considered significant. RESULTS: The study included 39 paraplegic or tetraplegic men with spinal cord injury. The mean age was 35.52±9.78 years, and the mean time since injury was 6.09±5.55 years. The mean biochemical levels were: 19.0 ±6.98 ng/mL for vitamin D; 9.54±0.52 mg/dL for total calcium; and 34.81±10.84 pg/mL for parathyroid hormone. Individuals with sun exposure for more than two hours daily had higher vitamin D levels than those exposed up to one hour per day (p=0.001). Linear regression identified an inverse relationship between lesion time and vitamin D levels (regression coefficient: -0.424; p=0.029), while the other parameters did not show significant differences regarding the time elapsed since the lesion. Subjects with income above four minimum wages had higher vitamin D values (mean 25.67±5.45 ng/mL) when compared to those with income up to four minimum wages (mean 18.43±6.79 ng/mL) (p=0.021). CONCLUSIONS: Levels of vitamin D were inversely correlated to the time elapsed since the spinal cord injury, probably due to insufficient sun exposure resulting from prolonged limitation of mobility. In addition, lower levels of vitamin D were associated to lower income. These factors may aggravate bone loss associated with decreased mobility resulting from spinal cord injury.

OBJETIVOS: Avaliar os níveis de vitamina D, hormônio paratireoide e cálcio em indivíduos com lesão medular e identificar fatores relacionados. MÉTODOS: Estudo transversal incluiu homens com lesão da medula espinhal, vivendo na Região Sul do Brasil. Foi aplicado um questionário para avaliar dados socioeconômicos, hábitos de vida e saúde. Foi investigado o tempo transcorrido após a lesão medular. A vitamina D foi avaliada no plasma por meio de cromatografia líquida; o cálcio e o hormônio paratireoideo foram dosados no soro por um método colorimétrico e eletroquimioluminescência respectivamente. Para a análise de dados, foram utilizadas regressão linear e teste do qui-quadrado. Valores de p<0,05 foram considerados significativos. RESULTADOS: O estudo incluiu 39 homens paraplégicos ou tetraplégicos com lesão da medula espinhal. A média de idade foi de 35,52±9,78 anos e o tempo médio de lesão foi de 6,09±5,55 anos. As médias dos níveis bioquímicos foram: 19,0±6,98 ng/mL para vitamina D, 9,54±0,52 mg/dL para cálcio total e 34,81±10,84 pg/mL para hormônio paratireoideo. Indivíduos com exposição ao sol por mais de duas horas por dia apresentaram maiores níveis de vitamina D do que os expostos até uma hora por dia (p=0,001). A regressão linear identificou uma relação inversa entre o tempo de lesão e os níveis de vitamina D (coeficiente de regressão: -0,424; p=0,029), enquanto os outros parâmetros não apresentaram diferença significativa em relação ao tempo decorrido desde a lesão. Os indivíduos com renda acima de quatro salários mínimos apresentaram maiores valores de vitamina D (média de 25,67±5,45 ng/mL) quando comparados com aqueles com renda até quatro salários mínimos (média 18,43±6,79 ng/mL) (p=0,021). CONCLUSÕES: Os níveis de vitamina D foram inversamente correlacionados com o tempo decorrido desde a lesão da medula espinhal, provavelmente devido à exposição insuficiente ao sol resultante da limitação prolongada da mobilidade. Níveis mais baixos de vitamina D foram associados a menor renda. Estes fatores podem agravar a perda óssea associada à diminuição da mobilidade resultante da lesão da medula espinhal.

Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load

OBJECTIVE: To evaluate the factors associated with plasma concentrations of atazanavir (ATV) in a cohort of well-controlled HIV infected subjects (undetectable viremia). Design: Cross-sectional study where 69 subjects were consecutively enrolled between April and November, 2011. METHODS: Patients had to be on atazanavir for at least six months, undetectable viral load for a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than 200 cells/mm³, and aged between 18 years and 70 years old. Exclusion criteria were pregnancy, any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir plasma levels were measured by ultra-performance liquid chromatography. RESULTS AND DISCUSSION: Overall, 54 patients (mean age of 47 years and 50% women) were included in the analysis. Those without ritonavir (unboosted atazanavir) had statistically lower plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and total and indirect bilirubin were statistically associated with plasma concentration of atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). no statistical association was found among gender, ethnicity, age, weight, body mass index (BMI), lipid profile, and the plasma concentration of atazanavir. CONCLUSION: in summary, as expected, concomitant ritonavir use was the only factor associated with atazanavir plasma levels. prospective studies with a larger sample size might help to observe an association of atazanavir concentrations to other characteristics such as body weight, since the p-value showed to be close to significance (p = 0.068).

Monitoring imatinib plasma concentrations in chronic myeloid leukemia

Imatinib has proved to be effective in the treatment of chronic myeloid leukemia, but plasma levels above 1,000 ng/mL must be achieved to optimize activity. Therapeutic drug monitoring of imatinib is useful for patients that do not present clinical response. There are several analytical methods to measure imatinib in biosamples, which are mainly based on liquid chromatography with mass spectrometric or diode array spectrophotometric detection. The former is preferred due to its lower cost and wider availability. The present manuscript presents a review of the clinical and analytical aspects of the therapeutic drug monitoring of imatinib in the treatment of chronic myeloid leukemia. The review includes references published over the last 10 years. There is evidence that the monitoring of plasmatic levels of imatinib is an useful alternative, especially considering the wide pharmacokinetic variability of this drug.

Standardization of method for determining glycosylated hemoglobin (Hb A1c) by cation exchange high performance liquid chromatography / Padronização de método para determinação de hemoglobina glicosilada (Hb A1c) por troca de cátions de alto desempenho cromatografia líquida

Hemoblobin A1c is the most important parameter for the monitoring of metabolic control of patients with diabetes mellitus. The purpose of this study was to adapt the Mono S method to a conventional HPLC system, allowing highly selective HbA1c determination without the acquisition of kits or the use of dedicated systems The results obtained were compared to the Tinaquant® immune turbidimetric method and the Bio-Rad Variant® chromatographic method. The developed method presented intra-study precision (C.V. percent) of 1.39-3.65 and inter-study precision (C.V. percent) of 2.80-3.02 percent. The determination coefficients among methods were: HPLC Mono S x Tinaquant®: r²: 0.9856 (n=60) and HPLC Mono S x HPLC Bio-Rad Variant®: r²: 0.9806 (n=16). A conversion equation between HPLC Mono S and Bio-Rad Variant® was calculated allowing yielding comparable and interchangeable values. The HPLC Mono-S is a precise, low-cost method which yields similar values to the Bio-Rad Variant® method on conventional HPLC equipment.

A hemoglobina A1c é o parâmetro laboratorial mais importante no monitoramento do controle metabólico de pacientes portadores de diabetes melito. Dentre as metodologias existentes para a quantificação desta fração de hemoglobina, a cromatografia líquida de alta eficiência (CLAE) baseada em troca catiônica apresenta a melhor precisão, sendo o método de escolha. O objetivo deste trabalho foi adaptar o método Mono S a um sistema de CLAE convencional permitindo a disponibilidade da determinação altamente seletiva de Hb A1c sem a aquisição de kits e comparar os resultados obtidos com o método imunoturbidimétrico Tinaquant® (Roche®) e com o método de cromatografia líquida Bio-Rad Variant®. O método desenvolvido apresentou precisão intra-ensaio de 1,39-3,65 por cento e inter-ensaio de 2,80-3,02 por cento. Os coeficientes de determinação entre os métodos foram: CLAE Mono S x Tinaquant®: r² = 0,9856 (n=60) e CLAE Mono S x Bio-Rad Variant®: r² = 0,9806 (n=16). Não foram observadas diferenças entre CLAE Mono S e Bio-Rad Variant® através de gráfico de Bland-Altman e regressão de Passing-Bablok. Foi obtida uma equação de conversão entre os valores do método teste e os valores obtidos por métodos rastreáveis ao National Glycohemoglobin Standardization Program (NGSP), permitindo a obtenção de valores comparáveis e intercambiáveis entre as metodologias com o uso de instrumentos convencionais de CLAE e com custo reduzido.

Estudo pré-analítico e de validação para determinação de malondialdeído em plasma humano por cromatografia líquida de alta eficiência, após derivatização com 2.4-dinitrofenilhidrazina / Preanalytical and validation studies for the determination of malondialdehyde in human plasma through high performance liquid chromatography after derivatization with 2.4-dinitrophenylhydrazine

O malondialdeído (MDA) é um importante biomarcador utilizado na avaliação do estresse oxidativo. O objetivo deste estudo foi desenvolver uma metodologia para a quantificação plasmática de MDA, através de cromatografia líquida de alta eficiência com detecção por arranjo de diodos (CLAE-DAD), após processo de derivatização com 2,4-dinitrofenilhidrazina (DNPH), avaliando as principais variáveis pré-analíticas. A curva de calibração em plasma (0 a 40 µM) apresentou elevada linearidade (r²=0,998). Os principais parâmetros de validação foram: recuperação absoluta: 78 por cento; limite de detecção: 0,11 µM e limite de quantificação: 0,38 µM. Os valores de MDA determinados em indivíduos adultos saudáveis (n=38) foram 3,31 ± 0,38 µM (média ± DP). Estudos de estabilidade do padrão de MDA, reagente derivatizante e MDA plasmáticos, indicaram que a solução padrão pode ser armazenada a -20 e 4 ºC.

Malondialdehyde (MDA) is an important biomarker for the evaluation of oxidative stress status. The aim of this study was to develop a method for plasma MDA quantification by high performance liquid chromatography with diode-array detection (HPLC-DAD), following derivatization with 2,4-dinitrophenylhydrazine (DNPH), evaluating the main preanalytical variables. The calibration curve in plasma (0 to 40 µM) presented high linearity (r² = 0.998). Main validation parameters were: recovery: 78 percent; LOD: 0.11 µM and LOQ: 0.38 µM. The MDA values obtained in healthy volunteers (n=38) were 3.31 ± 0.38 µM (mean ± SD). Stability studies of MDA standard solution and derivatizing reagent and plasma MDA indicated that the standard solution can be stored at -20 and 4 ºC, remaining stable for at least 30 days.